Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...

Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches — continuous therapy with Bruton’s tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to living their lives to the fullest after being diagnosed with chronic ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

Do you remember the early days of social media? The promise of connection, of democratic empowerment, of barriers crumbling and gates opening? In those heady days, the co-founder of Twitter said that ...

Ever wondered how social media platforms decide how to fill our feeds? They use algorithms, of course, but how do these algorithms work? A series of corporate leaks over the past few years provides a ...

AbbVie seeks FDA approval for Venclexta and Calquence combination for untreated CLL, following positive AMPLIFY trial results. The combination regimen showed a 35% reduction in disease progression or ...

In the age of targeted therapy, what’s the best long-term strategy to treat chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries? Should treatment be continuous to achieve ...

Both time-limited therapy and continuous therapy for chronic lymphocytic leukemia (CLL) have potential benefits and drawbacks. The best choice, a joint decision between clinician and patient, should ...